Welcome to our dedicated page for Ulta Beauty SEC filings (Ticker: ULTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ulta Beauty鈥檚 filings do more than list numbers鈥攖hey reveal how a leading beauty retailer balances product sales, salon services, and a 40-million-member loyalty program. If you have ever asked, 鈥淲here can I find Ulta Beauty鈥檚 quarterly earnings report 10-Q filing?鈥� or 鈥淗ow does the company recognize loyalty points in its 10-K?鈥�, this page has the answers.
Stock Titan layers AI-powered summaries onto every document, so understanding Ulta Beauty SEC documents with AI becomes straightforward. Open a 10-K and see the loyalty points liability called out in plain English. Scan an 8-K and get Ulta Beauty 8-K material events explained before markets react. AG真人官方-time alerts flag Ulta Beauty insider trading Form 4 transactions, letting you monitor executive stock moves the moment they hit EDGAR.
Here鈥檚 what you鈥檒l uncover:
- Annual report 10-K simplified鈥攑rivate-label margin trends, gift-card breakage, and salon service profitability.
- Quarterly earnings report 10-Q鈥攊nventory build heading into holiday season, e-commerce growth, and segment sales shifts.
- Form 4 insider transactions real-time鈥攖rack CEO and CFO share activity for governance insights.
- Proxy statement executive compensation鈥攃ompare bonus metrics to revenue goals.
- 8-K material events鈥攕tore openings, leadership changes, and vendor partnerships.
Whether you鈥檙e performing Ulta Beauty earnings report filing analysis, studying vendor allowances, or simply need Ulta Beauty SEC filings explained simply, our platform reduces hours of reading to minutes of clarity. Save time, stay informed, and make decisions backed by every disclosure Ulta files.
Core Scientific, Inc. (NASDAQ: CORZ) filed a Form 8-K announcing it has signed a definitive Agreement and Plan of Merger with privately-held CoreWeave, Inc. dated 7 July 2025. Under the agreement Miami Merger Sub I, a wholly-owned subsidiary of CoreWeave, will merge with and into Core Scientific, leaving Core Scientific as a wholly-owned subsidiary of CoreWeave.
Merger consideration: each share of Core Scientific common stock will be converted into the right to receive 0.1235 shares of CoreWeave Class A common stock (the 鈥淓xchange Ratio鈥�). Treasury shares and shares already owned by either party will be cancelled with no consideration.
Equity awards and warrants will be treated as follows:
- Unvested RSUs and PSUs held by specified executives and non-employee directors vest in full and are exchanged for CoreWeave shares at the Exchange Ratio.
- Other RSUs/PSUs roll over into equivalent CoreWeave awards, preserving original vesting schedules (performance metrics convert to time-based for most PSUs).
- 鈥淚n-the-money鈥� stock options convert into CoreWeave options according to a Black-Scholes-based formula tied to the Exchange Ratio; out-of-the-money options are cancelled without consideration.
- Tranche 1 and Tranche 2 warrants will convert into new CoreWeave warrants for a proportionate number of shares with exercise prices adjusted by the Exchange Ratio.
Closing conditions include: (1) majority approval by Core Scientific shareholders, (2) SEC effectiveness of a CoreWeave Form S-4, (3) HSR antitrust clearance, (4) absence of injunctions, and (5) Nasdaq listing of the new CoreWeave shares. Each party鈥檚 obligation is further conditioned on the other party鈥檚 representations being accurate and the absence of material adverse effect.
Termination provisions & fees: Either side may terminate for customary reasons (failure to close by 7 April 2026, injunction, breach, or shareholder vote failure). Core Scientific must pay CoreWeave a $270 million termination fee if the board withdraws its recommendation or enters a superior proposal before shareholder approval.
Executive compensation changes: The board approved (i) excise-tax gross-up agreements covering potential Section 4999 liabilities triggered by the transaction and (ii) separation letters providing each named executive two years鈥� salary plus bonus and 24 months of COBRA premiums upon closing, conditioned on continued employment through closing.
Next steps: CoreWeave will file a Form S-4 containing a joint proxy statement/prospectus; Core Scientific shareholders will receive definitive materials before voting. No earnings data were included in this filing.
Nuveen is distributing a Definitive Proxy Statement for 14 closed-end municipal bond funds, including Nuveen New York Municipal Value Fund (NYSE: NNY). Shareholders of record on 20 June 2025 are invited to a virtual annual meeting on 14 August 2025 at 2:00 p.m. CT via www.meetnow.global/MNRRJJC.
Main agenda
- Election of Board Members: four Class III directors for Municipal Income; four Class I directors for five funds (incl. NNY); and five directors for eight funds that issue preferred shares (three elected by all share classes, two by preferred shareholders only).
- Transaction of any other proper business.
The proposed slate is entirely composed of independent candidates. If elected, Class I nominees will serve until the 2028 meeting; preferred-share directors will serve until the 2026 meeting. The document details board structure, committee responsibilities, director qualifications and a comprehensive breakdown of director compensation. Effective 1 January 2025, the annual retainer for independent directors was maintained at $350,000, while committee retainers rose modestly (e.g., Audit Committee from $30,000 to $35,000). No fund performance figures or changes to investment policy are proposed.